Jan 08, 2024 / 04:15PM GMT
Richard Vosser - JPMorgan Chase & Co, Research Division - Senior Analyst
Welcome to the Novartis presentation at the 42nd JPMorgan Healthcare Conference. I'm Richard Vosser, European pharma analyst with JPMorgan. It's my great pleasure to welcome Vas Narasimhan, the CEO of Novartis today. Before I hand over to Vas, I'll just everyone, we're going to take Q&A after Vas' presentation in this room. Vas, welcome to the conference.
Vasant Narasimhan - Novartis AG - CEO
Thank you, Richard, and great to be here today. Always wonderful to be at JPMorgan to start the year and give all of you an update of where Novartis is and where we're going. And what I'd like to do is give you an overview of a little bit of our journey over the last few years and then talk about the future and I think pretty exciting prospects for us as a company.
Now when you look at our overall profile, in summary, we think we've come to a place where we really present investors an attractive story, a focused strategy with 4 core platforms -- 5 core platforms, 4 core TAs, strong
Novartis AG at JPMorgan Healthcare Conference Transcript
Feb 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers